Michael Dallas

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

Cornelia L. Trimble, Matthew P. Morrow, Kimberly A. Kraynyak et al. · The Lancet · 2015 · 714 citations

Medicine, Immunology, Oncology +17

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Pablo Tebas, ShuPing Yang, Jean Boyer et al. · EClinicalMedicine · 2020 · 282 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer

Charu Aggarwal, Roger B. Cohen, Matthew P. Morrow et al. · Clinical Cancer Research · 2018 · 144 citations · Full text

Life Sciences, Immunology, Oncology +17

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

Kimberly A. Kraynyak, Elliott Blackwood, Joseph Agnes et al. · The Journal of Infectious Diseases · 2022 · 61 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL

Prakash Bhuyan, Michael Dallas, Kim Kraynyak et al. · Human Vaccines & Immunotherapeutics · 2020 · 52 citations · Full text

Medicine, Gynecology, Oncology +17